European Markets for Prosthetic Vascular Grafts
This article was originally published in Start Up
Executive Summary
Many large and growing diseases, such as diabetes, cause vessel damage calling for replacement vascular grafts. The European market for prosthetic vascular grafts is today a $343 million industry and growing, according to "The European Prosthetic Vascular Grafts Market," a report just issued y Medtech Insight.
You may also be interested in...
In Vascular Disease, a Sustainable Model for Cell Therapy
If there's one word that ought to sum up the goal of cell therapy today, it's sustainability. Certainly that's the hope of using living cells to restore health and function to diseased tissues so that they perform as the body intended them to. But more to the point, in today's tough financing environment for venture-capital-backed start-ups, sustainability is the watchword for companies facing 15- to 20-year development curves. Tissue-engineered three-dimensional organs are complex, decades-long projects. Embryonic stem cells are much simpler in concept but are far from a commercial reality. Between those two extremes of tissue-engineering, however, there exist some well-defined opportunities, notably in the treatment of blood vessel disease. Start-ups Pervasis and Cytograft are gaining clinical validation in those areas.
Cytograft's New Lifeline for Vascular Surgery
The creation of durable vascular grafts has been a tantalizing objective for multitudes of companies and research efforts that have applied all the disciplines of medical science to it: tissue engineering, cell-therapies, biomaterials, drugs, and combinations of all of those technologies, but without much success. The complexities of creating a functional structure with biological properties has foiled many a research effort. But now Cytograft Tissue Engineering has a new take on tissue engineering. Cytograft produces a living conduit with the handling properties of a native vessel, built exclusively from the patient's own cells. Unlike previous approaches, Cytograft's Lifeline vascular graft does not require synthetic materials or exogenous scaffolds.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.